Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

$AEON Biopharma (AEON.US)$ AEON Biopharma Announces Clinical...

$AEON Biopharma(AEON.US)$ AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
1 MINUTE AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE

– FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine –

– An interim analysis from the ongoing Phase 2 study in chronic migraine will now be conducted and data are expected in Q2 2024; previously stated timeline for top-line data on the complete cohort remains on track for Q3 2024 –
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
10
Translate
Report
7770 Views
Comment
Sign in to post a comment
2504Followers
28Following
33KVisitors
Follow